Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Conditions: Ductal Carcinoma in Situ Interventions: Biological: MUC1 Peptide Vaccine; Drug: Hiltonol ®; Drug: Aromatase Inhibitor Sponsors: Finn, Olivera, PhD; A Glimmer of Hope Foundation; Breast Cancer Research Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Research | Vaccines